Rituximab: modes of action, remaining dispute and future perspective
Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of o...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Published: |
Future Medicine Ltd.
2014
|
| Subjects: |
| _version_ | 1796861276825059328 |
|---|---|
| author | Abulayha, Abdulmunem Bredan, Amin S. El-Enshasy, Hesham Ali Daniels, Ian |
| author_facet | Abulayha, Abdulmunem Bredan, Amin S. El-Enshasy, Hesham Ali Daniels, Ian |
| author_sort | Abulayha, Abdulmunem |
| collection | ePrints |
| description | Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research. |
| first_indexed | 2024-03-05T19:53:54Z |
| format | Article |
| id | utm.eprints-62489 |
| institution | Universiti Teknologi Malaysia - ePrints |
| last_indexed | 2024-03-05T19:53:54Z |
| publishDate | 2014 |
| publisher | Future Medicine Ltd. |
| record_format | dspace |
| spelling | utm.eprints-624892017-06-15T01:14:12Z http://eprints.utm.my/62489/ Rituximab: modes of action, remaining dispute and future perspective Abulayha, Abdulmunem Bredan, Amin S. El-Enshasy, Hesham Ali Daniels, Ian RC Internal medicine Less than two decades ago, immunotherapy joined chemotherapy and radiotherapy as an effective approach for the treatment of cancer. The anti-CD20 monoclonal antibody, rituximab, is now used to treat almost all types of non-Hodgkin's B-cell lymphomas, and it could be useful in the treatment of other diseases with B-cell involvement. Upon binding, rituximab induces death of the target cells. It seems to act not only by activating immune system defense mechanisms such as complement-dependent and antibody-dependent cellular cytotoxicity, but also by inducing direct cell death. In this paper, we review current knowledge on rituximab mechanisms of action, with particular attention to its direct effects, and also highlight potential future avenues of research. Future Medicine Ltd. 2014 Article PeerReviewed Abulayha, Abdulmunem and Bredan, Amin S. and El-Enshasy, Hesham Ali and Daniels, Ian (2014) Rituximab: modes of action, remaining dispute and future perspective. Future Oncology, 10 (15). pp. 2481-2492. ISSN 1479-6694 http://dx.doi.org/10.2217/fon.14.146 DOI:10.2217/fon.14.146 |
| spellingShingle | RC Internal medicine Abulayha, Abdulmunem Bredan, Amin S. El-Enshasy, Hesham Ali Daniels, Ian Rituximab: modes of action, remaining dispute and future perspective |
| title | Rituximab: modes of action, remaining dispute and future perspective |
| title_full | Rituximab: modes of action, remaining dispute and future perspective |
| title_fullStr | Rituximab: modes of action, remaining dispute and future perspective |
| title_full_unstemmed | Rituximab: modes of action, remaining dispute and future perspective |
| title_short | Rituximab: modes of action, remaining dispute and future perspective |
| title_sort | rituximab modes of action remaining dispute and future perspective |
| topic | RC Internal medicine |
| work_keys_str_mv | AT abulayhaabdulmunem rituximabmodesofactionremainingdisputeandfutureperspective AT bredanamins rituximabmodesofactionremainingdisputeandfutureperspective AT elenshasyheshamali rituximabmodesofactionremainingdisputeandfutureperspective AT danielsian rituximabmodesofactionremainingdisputeandfutureperspective |